Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - AUXILIUM PHARMACEUTICALS INC | d8k.htm |
 1 November 2009 (NASDAQ: AUXL) Exhibit 99.1 |
 2 Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking
statements” for purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market, growth potential and therapeutic benefits of the Company’s product candidates, including those for the treatment of Dupuytren’s contracture,
Peyronie’s disease, and Frozen Shoulder syndrome; interpretation of market research data;
competition within certain markets relevant to the Company’s product candidates; interpretation of clinical results, including the efficacy and tolerability of the Company’s product candidates; the timing of the commencement and completion of
clinical trials and the timing of reporting of results therefrom; the timing of any action by
the U.S. Food and Drug Administration on the Biologics License Application for XIAFLEX™ (collagenase clostridium histolyticum– formerly referred to as AA4500) for the treatment of Dupuytren’s contracture and the approval thereof;
the timing of the release of results from the phase IIb trial for XIAFLEX for the treatment of
Peyronie’s disease; the timing of the launch of XIAFLEX for the treatment of Dupuytren’s contracture in the U.S. and the design of the risk management plan; the timing of the initiation of phase III for XIAFLEX for the treatment of
Peyronie’s disease; the Company’s ability to manufacture XIAFLEX at the Company’s
Horsham facility in sufficient quantities to meet several years of global launch expectations given annual capacity at current yields; the timing of the filing by Pfizer of the Marketing Authorization Application for XIAFLEX for the treatment of
Dupuytren’s contracture in the European Union; competitive developments affecting the
Company’s products and product candidates, including generic competition; the success of the Company’s development activities; future Testim market share, prescriptions and sales growth and factors that may drive such growth; size and
growth potential of the testosterone replacement therapy market and the gel segment thereof and
factors that may drive such growth; the protection for Testim afforded by U.S. Patent No. 7,320,968, and those issued on October 27, 2009 and their listing in the Orange Book, the value of extending patent protection
for Testim through January 2025, the value and likelihood that patents will be granted from the
continuation and divisional applications filed by CPEX Pharmaceuticals, Inc.; the impact of the filing by Upsher-Smith Laboratories, Inc. of an ANDA for a testosterone gel; the Company’s development and operational goals
and strategic priorities for fiscal 2009; the ability to fund future operations; and the
Company’s expected financial performance during 2009 and financial milestones that it may achieve for 2009, including 2009 net revenues, research and development spending, selling, general and administrative expenses, stock-based
compensation expenses, and net loss. All remarks other than statements of historical facts
made during this presentation, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the
words “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“expect,” and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various
factors, including general financial, economic, regulatory and political conditions affecting
the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2008 and in Auxilium’s Quarterly Report on Form 10-Q for the period ended June 30,
2009 under the heading "Risk Factors“, which is on file with the Securities and
Exchange Commission (the “SEC”) and may be accessed electronically by means of the SEC’s home page on the Internet at http://www.sec.gov or by means of the Company’s home page on the Internet at http://www.auxilium.com under the heading
“Investor Relations - SEC Filings.” There may be additional risks that the
Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should not rely on any
such factors or forward-looking statements. In addition, forward-looking statements provide the Company’s expectations, plans or forecasts of
future events and views as of the date of this presentation. The Company anticipates that
subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims
any obligation to do so. These forward-looking statements should not be relied upon as
representing the Company’s assessments as of any date subsequent to the date of this presentation. |
 3 Focused on Sustainable Long-term Growth XIAFLEX New Territories XIAFLEX New Indications XIAFLEX Peyronie’s XIAFLEX Dupuytren’s Testim |
 4 • Completed enrollment in Peyronie’s Phase IIb (Feb. 2) • Filed BLA for Dupuytren's Contracture (Feb. 27) • Received FDA priority review (Apr. 28) and PDUFA Date (Aug. 28) • Secured $30 M Revolving Credit Line with Silicon Valley Bank (Aug. 4) • CORD I published in New England Journal of Medicine (Sept. 3) • 12 month Dupuytren's Contracture safety presented at ASSH (Sept. 5) • Unanimous 12-0 FDA Arthritis Advisory Committee vote recommending approval of XIAFLEX (Sept. 16) 2009 Milestones Achieved |
 5 • U.S. Dupuytren’s Contracture Launch (~ 60 days post-approval) • Top-line results of Peyronie's Phase IIb Study (Dec 09) • Pfizer files MAA for Dupuytren’s Contracture in EU (Early 2010) • Initiation of Peyronie's Phase III Studies (2010) Timing Dupuytren’s Peyronie’s Anticipated XIAFLEX Events 2009 2010 |
 6 Pipeline Continues to Advance Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH
PRE-CLINICAL PHASE I PHASE II PHASE
III MARKET TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Pain Hormone & Urology |
 7 XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA
|
 8 XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet
needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights generate and support growth – Build company in North America – Partnered with Pfizer in EU for Dupuytren’s and Peyronie’s – Opportunity to add additional indications – Rights for other territories or indications could generate additional cash • We believe there are at least 450,000 potential patients annually in U.S. and
EU for Dupuytren’s & Peyronie’s indications or > $1 Billion
opportunity, based on market research and analysis
|
 9 Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be reserved for advanced disease due to unpredictable results, complications, long recovery and recurrence/additional surgeries |
 10 Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation |
 11 XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases
in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow cleavage XIAFLEX XIAFLEX End products |
 12 CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture • Primary endpoint is reduction in contracture to within 0 - 5° of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Secondary endpoints to measure clinical improvement and range of motion (ROM) > 50% improvement in contracture > mean change in primary joint degree of contracture > mean change in degrees of finger flexion minus extension (ROM) • Published in September 3 edition of The New England Journal of
Medicine rd |
       13 Results Are Comparable to Surgery at the Joint Level Hurst et al. NEJM 2009 Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) P < 0.001 P < 0.001 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) P < 0.001 MP = metacarpophalangeal PIP = proximal interphalangeal Placebo (N=34) Placebo (N=69) |
 14 XIAFLEX Was Well-Tolerated in the CORD I Study • The overwhelming majority of adverse events were local reactions and rates were consistent with prior XIAFLEX trials • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days • No deaths, clinically meaningful changes in grip strength, arterial injuries or nerve injuries were reported • No clinically meaningful changes in laboratory values • No clinically meaningful systemic allergic reactions |
 15 XIAFLEX is a Potential, First-line Nonsurgical Option for Patients with Dupuytren’s Contracture • Efficacy should compare favorably to surgery – Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake • Early intervention may be the best treatment approach • A significant number of patients with Dupuytren’s contractures should be
candidates for treatment with XIAFLEX • 12 month estimated recurrence for 830 joints of 6.7% is comparable to earlier single center study • Safety profile compares favorably to surgery – No systemic exposure and no systemic hypersensitivity reactions – No nerve injuries and no arterial injuries |
 16 XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications • Common adverse events and rates were consistent with prior XIAFLEX trials • Most AEs were mild or moderate in severity, all were confined to treated extremity and
self-limiting with a median duration of 10 days • Serious Adverse Events Number Rate/Inj. Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Tendonitis 1 0.04% Boutonniere Deformity 1 0.04% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Sensory Disturbance 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 10 0.39% Note: > 2,600 injections in approximately 1000 patients from CORD, JOINT
and PK studies as of October 29, 2008. These SAEs occurred in the same
patient |
 17 XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture |
 18 XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in France, UK, Sweden through 2018 > Pending in Germany and Denmark • Highly Purified Collagenase product and manufacturing patent filed (if issued, expected expiry 2027) |
 19 XIAFLEX Supply Chain • API produced in Horsham, PA – 2°- 8°C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophilization: Hollister-Stier; WA – FDA and EMEA-approved facility – Supplies U.S. and EU markets with injectable forms |
 20 Dupuytren’s Contracture –an Unmet Medical Need 1 NEJM 2009 2 Hueston 1963 3 Skoog 1948 4 Mikkelsen 1976 5 Tubiana 2006 • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to 27 Million, in U.S. and EU, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients • On average, patients have 2.2 affected joints at the time of diagnosis, and about half of patients have bilateral disease • Recurrence rate in surgical patients 4,5 > 30% during 1st and 2nd postoperative years > 55% in 10 years • We believe Dupuytren’s contracture is under-diagnosed and under-treated 1 1 2 3 |
 21 Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeons have been interviewed to estimate market size (401 in U.S.; 170 in Europe) and 391 have given feedback on potential usage of XIAFLEX (221 U.S.; 170 Europe) • Second study (n=444 total & 340 in depth) was designed to provide 95% confidence level and 7.5% margin of error |
 22 Source: 2006 Auxilium research and analysis Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU |
 23 Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~1M patients annually seeking treatment in U.S. and
EU • Sustainable patient pool – New patients within an ageing population • Average of 2.2 joints affected at time of diagnosis • ~ 50% of patients have bilateral disease – Disease progression to additional joints – High recurrence rate for surgery • No nonsurgical competition - pricing expected to be comparable to surgery • Market development represents upside |
 24 1 Smith BH. Am J Clin Pathol. 1966;45:670-678. 2 Somers KD, Dawson DM. J Urol. 1997;157:311-315. Peyronie’s Disease is a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/ deviation, penile shortening, indentations, and/or erectile dysfunction > May experience difficulty with sexual intercourse, loss of self-esteem, and depression • There are no approved therapies for the treatment of Peyronie’s disease 2 1 |
 25 Peyronie’s Disease - an Unmet Medical Need 1 Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. 2 Smith BH. Am J Clin Pathol. 1966;45:670-678. 3 Lindsay MB, J Urol. 1991;146:1007-1009. 4 Nyberg L, J Urol.128: 48, 1982 • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men > Actual prevalence may be higher, based on autopsies • Prevalence rate increases with age > The average age of disease onset is 53 years • High association with other diseases such as: > Diabetes, erectile dysfunction (ED), Dupuytren’s contracture, plantar fascial contracture, tympanosclerosis, gout, and Paget’s disease • We believe Peyronie’s disease is under-diagnosed and under-treated
3 1 4 2 |
 26 Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to attempt other treatments first |
 27 Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser and ultrasound therapy, and orthovoltage radiation |
             28 Promising Phase II Data with 25% Reduction in the Angle of Deviation for Most Patients 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% |
 29 Peyronie’s Phase IIb Study Top-line Data Expected in December 2009 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to maintain a rigid erection and have a penile contracture between 30 and 90 degrees. – Stratification occurs by the degree of penile curvature (i.e. 30° to 60° versus > 60°). • Active dosing period has been completed. – Patients will be monitored for 36 weeks following first injection.
|
 30 Peyronie’s Phase IIb Study Design Arm Study Drug Plaque Modeling Targeted Number of Patients A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.
|
 31 Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyronie’s disease bother – intercourse discomfort – intercourse constraint • PRO likely to be used as a primary efficacy endpoint in Phase III clinical trials. |
 32 Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given feedback on potential usage of XIAFLEX (223 U.S.; 160 Europe) • Second study (n=472 total & 333 in depth) was designed to provide 95% confidence level and 7.5% margin of error
|
 33 Source: 2006 Auxilium research and analysis Annually, >210,000 Peyronie’s Candidates could Exist between U.S. and Europe |
 34 XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in France, UK, and Ireland (expiry 2020) > Pending in Germany, Denmark, and Norway • Highly Purified Collagenase product and manufacturing patent filed (if issued, expected expiry 2027) |
 35 Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pfizer’s territories • Primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. • Exclusive rights to commercialize XIAFLEX for Dupuytren’s contracture and Peyronie’s disease > 27 member countries of European Union (EU) and 19 other European and Eurasian countries • Primarily responsible for: • EU regulatory activities • All commercialization activities • Phase IV clinical development • First EU only partnership |
 36 Testim ® 1% Testosterone Gel: Near-Term Growth Driver |
 37 Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract 2006 • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal* > We estimate that <10% of affected population receives treatment • We believe diagnosis is increasing through education and awareness |
         38 Patient Results Were Proven in Clinical Studies Note: Adjusted geometric means (CV b %) of a single-dose complete crossover study of 29 hypogonadal men. Total Testosterone 2,000 3,000 4,000 5,000 6,000 Mean AUC 0-24 (ng*h/dL) Testim AndroGel Free Testosterone 0 50 100 150 200 250 Mean AUC 0-24 (ng*h/dL) Testim AndroGel • 16 clinical studies involving approx. 1,800 patients > largest placebo-controlled study ever conducted • Clinical trial of Testim vs. AndroGel > Testim provides 30% higher testosterone absorption (p<0.001) ® ® (50 mg testosterone), randomized, |
 39 Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 0 100 200 300 400 500 600 700 800 900 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) Sept. 2009 L12M: 26.9% |
 40 Testim® Quarterly Net Revenues and Scripts ($ in millions) Continuing Track Record of Consistent Revenue Growth 3Q09 Net Testim Revenues Y/Y Growth: +25.1% 3Q09 TRX Y/Y Growth: +17.3% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.2M $113.3M |
 41 Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims
for Testim issued October 27, 2009; expire 2023 • Upsher-Smith Laboratories, Inc. filed an ANDA with paragraph IV certification
referring to the ’968 patent; AUXL filed lawsuit under Hatch-Waxman on
Dec. 4, 2008; 30 month stay expires June 2011 ROW • Patent issued in Canada; expires 2023 • Patent issued in Europe; expires 2023 • Patents granted and applications pending in numerous countries worldwide
|
 42 FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response
was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic versions of Testim and disagreed with
other statements. • Although not commenting upon any filing in particular, the FDA did state that
"The practical effect of this determination is that any application for a
testosterone gel product that has different penetration enhancers than the
reference listed drug cannot be submitted as an ANDA and, instead, will have
to be submitted as an NDA under section 505(b) of the Act.“ • We will be interested to see what impact that has in the future.
|
 43 2009 Q3 ’09 9M ‘09 Guidance Revenues $42.1 $116.0 $155-165 R&D Expense $12.8 $40.0 $45-50 SG&A Expense $34.7 $90.5 $120-130 Net Loss ($14.9) ($41.6) ($50-55) Stock – Based Comp Expense $4.1 $13.5 $16-19 Cash & Cash Equivalents $192.3 Q3 ‘09 Financial Results and 2009 Guidance ($ Millions) Currently, approximately 47.2 million shares issued & outstanding. Additional 5.5
million shares subject to issuance from stock options & warrants
|
 44 Strategic Priorities in 2009 and 2010 • Obtain approval from the FDA in Dupuytren’s Contracture; • Execute a successful launch in the U.S. for XIAFLEX in Dupuytren’s contracture approximately 60 days after our approval; • Complete enrollment in the observational long term follow up study of Dupuytren’s contracture patients; • Support Pfizer in preparing for XIAFLEX EU submission in early 2010; • Release top line results from XIAFLEX Phase IIb trial for Peyronie’s disease in December 2009; and • Vigorously defend Testim IP and continue to grow revenues.
|
 45 Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories |
 46 Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com November 2009 (NASDAQ: AUXL) |